Danish allergy immunotherapy specialist ALK Abello today posted financial results which pleased investors, with its shares rising 6.2% to 199.50 kroner.

The UK’s NHS Business Services Authority's annual 'Prescribing for Diabetes - England 2015/16 to 2024/25' report reveals that diabetes treatments now account for 15% of all NHS prescription spending, ...

For what is reportedly the first time in decades, the American Academy of Pediatrics (AAP) has contradicted the US Centers for Disease Control and Prevention (CDC) over its recommended immunization ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

The UK’s National Institute for Health and Care Excellence (NICE) has today (August 21) recommended the use of Japanese pharma major Astellas’ enfortumab vedotin with MSD’s Keytruda (pembrolizumab) ...

Ireland-headquartered Jazz Pharmaceuticals and Denmark’s Saniona have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, ...

Japanese ophthalmology major Santen Pharmaceutical has licensed the Asia rights to Chinese biopharma RemeGen’s ...

VantAI, a specialist in generative AI for proximity drug discovery, and Halda Therapeutics, a company focused on regulated ...

Swiss pharma company Idorsia announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has ...

Elix has announced that fellow Japanese firm Kyorin Pharmaceutical has adopted Elix Discovery, its proprietary AI-powered ...

PTC Therapeutics yesterday revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...